Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 14/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6774792 | 1.00 | CCR3 (0.55) | CCR3NPC1POLBMAOBRAB9A | |
| SCHEMBL6768909 | 0.96 | CCR3 (0.50) | CCR3NPC1POLBMAOBRAB9A | |
| SCHEMBL6769109 | 0.96 | CCR3 (0.50) | CCR3NPC1POLBMAOBRAB9A | |
| SCHEMBL6774304 | 0.94 | CCR3 (0.47) | CCR3NPC1POLBMAOBRAB9A | |
| SCHEMBL6780143 | 0.94 | CCR3 (0.47) | CCR3NPC1POLBMAOBRAB9A | |
| SCHEMBL6773866 | 0.92 | EPHX1 (0.53) | CCR3NPC1POLBRAB9AEPHX1 | |
| SCHEMBL6773246 | 0.92 | EPHX1 (0.53) | CCR3NPC1POLBRAB9AEPHX1 | |
| SCHEMBL6774615 | 0.91 | CCR3 (0.51) | CCR3POLBSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6774937 | 0.91 | CCR3 (0.51) | CCR3POLBSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6772544 | 0.89 | RAB9A (0.56) | CCR3NPC1POLBRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6706735-B2 | NITROGEN COMPOUNDS SUCH AS N-(3-(4-BENZYL-2-PIPERIDINYL)PROPYL )-N'-(3-CYANOPHENYL)UREA, USED AS CHEMOTACTIC CYTOKINE CONTROLLERS ADMINISTERED FOR PROPHYLAXIS OF ASTHMA, ALLERGIES AND AUTOIMMUNE DISEASES | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-03-16 | — | — | US | disclosed |
| US-20030144273-A1 | 2-substituted-4-nitrogen heterocycles as modulators of chemokine receptor activity | WATSON PAUL S (US) | 2003-07-31 | — | — | US | disclosed |
| US-6441001-B1 | 2-substituted-4-nitrogen heterocycles as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144273-A1 | 2-substituted-4-nitrogen heterocycles as modulators of chemokine receptor activity | CCR3, CCR1, CCR4 | CCR3 1/4885NPC1 938/4885POLB 3050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.